Renowned Clinicians. Virology and Oncology Thought Leaders.
Our Scientific and Clinical Advisors bring a wide range of expertise to guide our growing clinical program, as well as to support the foundation of our scientific discovery efforts.
Ramy Ibrahim, M.D.
Vice President, Clinical Development Parker Institute for Cancer Immunotherapy
Ramy Ibrahim, M.D., is a recognized leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. Dr. Ibrahim currently serves as Chief Medical Officer and Vice President of Clinical Development at PICI.
At AstraZeneca, Dr. Ibrahim was the Vice President of Clinical Development for Immuno-oncology, leading the team developing multiple immunotherapies. Molecules developed under his leadership included durvalumab (anti-PD-L1 antibody) and tremelimumab (anti-CTLA-4 antibody) both with single drug and combination therapies with a focus on registrational studies in multiple indications including lung cancer, bladder cancer, and head and neck cancer.
As a member of the Bristol-Myers Squibb Immuno-oncology program, he served on the Yervoy (ipilimumab) clinical team supporting the program from early phase II through multiple global launches of the first FDA-approved immune checkpoint inhibitor. In addition, he played a key role in early development for nivolumab (PD-1), PD-L1 and CD137 antibody.
Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as the Society of Immunotherapy for Cancer (SITC), Ludwig Institute, the Cancer Research Institute, and Cancer Immunotherapy Trials Network (CITN). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.
Center Director and Professor, Biodesign Center for Immunotherapy, Vaccines and Virotherapy
Michael Morse, MD
Professor of Medicine, Professor in the Department of Surgery, Member of the Duke Cancer Institute
Brad Nelson, PhD
Distinguished Scientist and Director, Deeley Research Center
Kunle Odunsi, MD, PhD
Deputy Director, Chair of the Department of Gynecologic Oncology and Executive Director, Center for Immunotherapy, Co-Leader, Tumor Immunology and Immunotherapy Program Roswell Park Cancer Institute
Dr. Adekunle "Kunle" Odunsi is Deputy Director, Chair of the Department of Gynecologic Oncology, Executive Director of the Center for Immunotherapy, and Co-Leader of the Tumor Immunology and Immunotherapy research program at Roswell Park Comprehensive Cancer Center. He provides operational oversight for the scientific, clinical research and educational missions of Roswell Park, and monitors all research-related initiatives, steering development of programs and policies designed to transfer scientific discoveries to clinical settings.
He joined RoswelI's staff in 2001 as an Attending Surgeon in the Division of Gynecologic Oncology, Department of Surgical Oncology. After earning his medical degree from the University of Ife, Ile-Ife, Nigeria, in 1984, Dr. Odunsi completed postgraduate training in Obstetrics and Gynecology at the Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK. He was admitted to the Royal College of Obstetricians and Gynecologists in 1991.
Dr. Odunsi completed a research fellowship in Molecular Oncology and earned his Doctor of Philosophy at the Imperial Cancer Research Fund Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK. Subsequently, he completed residency training in Obstetrics & Gynecology at the Yale University School of Medicine, New Haven, CT, and clinical fellowship in Gynecologic Oncology at Roswell Park. He is a Fellow of the Royal College of Obstetricians and Gynaecologists in the United Kingdom. He is also a Fellow of the American College of Obstetricians and Gynecologists. In 2018, Dr. Odunsi was elected into the National Academy of Medicine, a distinguished lifetime designation that is considered one of the highest honors in health and medicine.
Dr. Odunsi is licensed by New York State and certified in Obstetrics & Gynecology by the American Board of Obstetrics and Gynecology. He is also board certified in the subspecialty of Gynecologic Oncology.
Dr. Odunsi’s research interests include the molecular characterization of tumor antigens in ovarian cancer and their application to the development of vaccine therapies for the disease.
Dr. Odunsi has authored or co-authored more than 300 journal publications and book chapters. He is Associate Editor for BMC Cancer. He also is an Ad Hoc Reviewer for the American Journal of Obstetrics and Gynecology, BLOOD, BMC Cancer, Cancer Immunity, Cancer Immunology Immunotherapy, Cancer Letters, Cancer Research, Clinical Cancer Research, Expert Opinion on Biological Therapy, Fertility and Sterility, Future Oncology, Gynecologic Oncology, International Journal of Cancer, Journal of Clinical Pathology, Journal of the Society for Gynecologic Investigation, The Lancet, Mayo Clinic Proceedings, Molecular Cancer Therapeutics, Oncogene, Oncology PLoS ONE and the Proceedings of the National Academy of Sciences, U.S.A.